1.Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C: The global burden of cancer 2013. JAMA oncology 2015, 1(4):505–527.
2.Siegel RL, Miller KD, Jemal A: Cancer statistics, 2018. CA: a cancer journal for clinicians 2018, 68(1):7–30.
3.DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A: International variation in female breast cancer incidence and mortality rates. Cancer Epidemiology and Prevention Biomarkers 2015, 24(10):1495–1506.
4.Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74–108.
5.Tiezzi DG: Rastreamento do câncer de mama no Brasil: ainda há tempo para refletirmos. CEP 2013, 14049:900.
6.Holmes D, Colfry A, Czerniecki B, Dickson-Witmer D, Espinel CF, Feldman E, Gallagher K, Greenup R, Herrmann V, Kuerer H: Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer. Annals of surgical oncology 2015, 22(10):3184–3190.
7.Guarneri V, Broglio K, Kau S-W, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. Journal of Clinical Oncology 2006, 24(7):1037–1044.
8.von Minckwitz G, Untch M, Blohmer J-U, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. Journal of Clinical Oncology 2012:JCO. 2011.2038. 8595.
9.Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H: Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast cancer 2013, 22(2):185–191.
10.de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Peeters M-JTV, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S: Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast cancer research and treatment 2010, 119(1):119–126.
11.Krijgsman O, Roepman P, Zwart W, Carroll JS, Tian S, de Snoo FA, Bender RA, Bernards R, Glas AM: A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast cancer research and treatment 2012, 133(1):37–47.
12.Wang-Lopez Q, Chalabi N, Abrial C, Radosevic-Robin N, Durando X, Mouret-Reynier M-A, Benmammar K-E, Kullab S, Bahadoor M, Chollet P: Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer? Critical reviews in oncology/hematology 2015.
13.Basu S, Hess S, Braad P-EN, Olsen BB, Inglev S, Høilund-Carlsen PF: The basic principles of FDG-PET/CT imaging. PET Clinics 2014, 9(4):355–370.
14.Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH: Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF–1α, CAIX, LDH–5, GLUT–1, MCT1 and MCT4. BMC cancer 2011, 11(1):167.
15.Chiche J, Brahimi‐Horn MC, Pouysségur J: Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. Journal of cellular and molecular medicine 2010, 14(4):771–794.
16.Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F: Role of monocarboxylate transporters in human cancers: state of the art. Journal of bioenergetics and biomembranes 2012, 44(1):127–139.
17.Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D, Schmitt F, Baltazar F: GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol 2011, 26(10):1279–1286.
18.Baenke F, Dubuis S, Brault C, Weigelt B, Dankworth B, Griffiths B, Jiang M, Mackay A, Saunders B, Spencer‐Dene B: Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival. The Journal of pathology 2015.
19.Doyen J, Trastour C, Ettore F, Peyrottes I, Toussant N, Gal J, Ilc K, Roux D, Parks S, Ferrero J: Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochemical and biophysical research communications 2014, 451(1):54–61.
20.Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, Schmitt F, Baltazar F: Monocarboxylate transporter 1 is up‐regulated in basal‐like breast carcinoma. Histopathology 2010, 56(7):860–867.
21.Kang SS, Chun YK, Hur MH, Lee HK, Kim YJ, Hong SR, Lee JH, Lee SG, Park YK: Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Japanese Journal of Cancer Research 2002, 93(10):1123–1128.
22.Bear HD, Anderson S, Smith RE, Geyer Jr CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B–27. J Clin Oncol 2006, 24(13):2019–2027.
23.Pinheiro C, Granja S, Longatto-Filho A, Faria AM, Fragoso M, Lovisolo SM, Lerário AM, Almeida MQ, Baltazar F, Zerbini M: Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors. Oncotarget 2015.
24.Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA, Schmitt F, Baltazar F: Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Archiv 2008, 452(2):139–146.
25.Vleugel M, Greijer A, Shvarts A, Van Der Groep P, Van Berkel M, Aarbodem Y, Van Tinteren H, Harris A, Van Diest P, Van Der Wall E: Differential prognostic impact of hypoxia induced and diffuse HIF–1α expression in invasive breast cancer. Journal of clinical pathology 2005, 58(2):172–177.
26.Kim HM, Jung WH, Koo JS: Site-specific metabolic phenotypes in metastatic breast cancer. Journal of translational medicine 2014, 12(1):1–17.
27.Baltazar F, Pinheiro C, Santos FM, Silva JA, Queirós O, Preto A, Casal M: Monocarboxylate transporters as targets and mediators in cancer therapy response. Histology and histopathology 2014, 29(12):1511–1524.
28.Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis? Nature Reviews Cancer 2004, 4(11):891.
29.Li X, Yu X, Dai D, Song X, Xu W: The altered glucose metabolism in tumor and a tumor acidic microenvironment associated with extracellular matrix metalloproteinase inducer and monocarboxylate transporters. Oncotarget 2016, 7(17):23141.
30.San-Millán I, Brooks GA: Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect. Carcinogenesis 2017, 38(2):119–133.
31.Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B–27. Journal of Clinical Oncology 2003, 21(22):4165–4174.
32.Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. Journal of clinical oncology 2002, 20(6):1456–1466.
33.Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. Journal of Clinical Oncology 2005, 23(25):5983–5992.
34.von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer J-U, Costa SD: Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast cancer research and treatment 2011, 125(1):145–156.
35.Yang Y, Im S-A, Keam B, Lee KH, Kim TY, Suh KJ, Ryu HS, Moon H-G, Han SW, Oh DY: Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. BMC cancer 2016, 16(1):515.
36.Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM: Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. Cancer 2010, 116(6):1431–1439.
37.Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical cancer research 2007, 13(8):2329–2334.
38.Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. Journal of clinical oncology 2005, 23(29):7265–7277.
39.Aomatsu N, Yashiro M, Kashiwagi S, Kawajiri H, Takashima T, Ohsawa M, Wakasa K, Hirakawa K: Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline. BMC cancer 2014, 14(1):400.
40.Euceda LR, Haukaas TH, Giskeødegård GF, Vettukattil R, Engel J, Silwal-Pandit L, Lundgren S, Borgen E, Garred Ø, Postma G: Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy. Metabolomics 2017, 13(4):37.
41.Betof A, Rabbani Z, Hardee M, Kim S, Broadwater G, Bentley R, Snyder S, Vujaskovic Z, Oosterwijk E, Harris L: Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. British journal of cancer 2012, 106(5):916.
42.Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G: Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocrine-related cancer 2006, 13(3):921–930.
43.Ivanova L, Zandberga E, Siliņa K, Kalniņa Z, Ābols A, Endzeliņš E, Vendina I, Romanchikova N, Hegmane A, Trapencieris P: Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells. Cancer chemotherapy and pharmacology 2015, 75(2):235–246.
44.Kumar GL, Rudbeck L: Education guide: immunohistochemical staining methods: pathology: Dako North America; 2009.
45.O’hurley G, Sjöstedt E, Rahman A, Li B, Kampf C, Pontén F, Gallagher WM, Lindskog C: Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers. Molecular oncology 2014, 8(4):783–798.
46.Pinder SE, Brown JP, Gillett C, Purdie CA, Speirs V, Thompson AM, Shaaban AM, Group TSotNBCS: The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. Journal of clinical pathology 2012:jclinpath–2012–201091.